Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. [electronic resource]
Producer: 20160512Description: 98 p. digitalISSN:- 1471-230X
- Antiviral Agents -- economics
- Benzimidazoles -- economics
- Cost-Benefit Analysis
- Drug Combinations
- Drug Therapy, Combination -- economics
- Female
- Fluorenes -- economics
- Genotype
- Hepacivirus -- genetics
- Hepatitis C, Chronic -- drug therapy
- Humans
- Interferons -- economics
- Macrocyclic Compounds -- economics
- Male
- Markov Chains
- Middle Aged
- Polyethylene Glycols -- therapeutic use
- Quality-Adjusted Life Years
- Ribavirin -- economics
- Ritonavir -- economics
- Simeprevir -- economics
- Sofosbuvir -- economics
- Sulfonamides -- economics
- Uracil -- analogs & derivatives
- Uridine Monophosphate -- analogs & derivatives
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.